Pakistan Business News API

{
    "totalArticles": 349060,
    "articles": [
        {
            "id": "dfbc33806215e78f53fe07edb26234b9",
            "title": "S&P 500 Posts Its First Two-Week Losses Since June: Markets Wrap",
            "description": "(Bloomberg) -- Wall Street ended a jittery week on a relatively quiet note, with stock traders digesting the rally of the past two days in the run-up to the Federal Reserve decision and the start of the big-tech earnings season.",
            "content": "(Bloomberg) — Wall Street ended a jittery week on a relatively quiet note, with stock traders digesting the rally of the past two days in the run-up to the Federal Reserve decision and the start of the big-tech earnings season.\nWhile the S&P 500 post... [9839 chars]",
            "url": "https://www.swissinfo.ch/eng/s%26p-500-posts-its-first-two-week-losses-since-june%3A-markets-wrap/90822975",
            "image": "https://www.swissinfo.ch/eng/wp-content/uploads/swissinfo-theme/swi-fallback-featured-image.jpg?ver=1765874457",
            "publishedAt": "2026-01-23T21:15:25Z",
            "lang": "en",
            "source": {
                "id": "eeded01d70417c9a7ab6fbbca0d1e830",
                "name": "SWI swissinfo.ch",
                "url": "https://www.swissinfo.ch"
            }
        },
        {
            "id": "935926e8d9ba2c016a65c8603318d685",
            "title": "Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy",
            "description": "CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026 , at 8:30 am Eastern Time , the Company will host a webcast and conference call to present 3-year",
            "content": "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a w... [1810 chars]",
            "url": "https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study",
            "image": "https://investorrelations.sarepta.com/static-files/d0b28561-f14e-4a81-8ebf-739357b1b541",
            "publishedAt": "2026-01-23T21:05:00Z",
            "lang": "en",
            "source": {
                "id": "dd1d9de5ddaea5bd7932bc022ff90174",
                "name": "Sarepta Therapeutics",
                "url": "https://investorrelations.sarepta.com"
            }
        },
        {
            "id": "4222038b0989d564d180054a9674b23a",
            "title": "Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma",
            "description": "Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.",
            "content": "A new first-line therapy treating patients with soft tissue sarcoma (STS)—combining anlotinib maintenance with chemotherapy—demonstrated favorable safety and efficacy in a single-arm, phase 2 trial, supporting further evaluation in randomized clinica... [4416 chars]",
            "url": "https://www.ajmc.com/view/anlotinib-plus-chemotherapy-shows-promising-results-in-advanced-soft-tissue-sarcoma",
            "image": "https://cdn.sanity.io/images/0vv8moc6/ajmc/20d163c7d750e5b10e32a841db89b682efaaabf4-1200x724.jpg",
            "publishedAt": "2026-01-23T19:47:22Z",
            "lang": "en",
            "source": {
                "id": "44c3dc8c76228ef5cb2e596d2bd52f75",
                "name": "The American Journal of Managed Care® (AJMC®)",
                "url": "https://www.ajmc.com"
            }
        }
    ]
}